Logotype for Apollo Tyres Ltd

Apollo Tyres (APOLLOTYRE) Q2 24/25 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Apollo Tyres Ltd

Q2 24/25 earnings summary

14 Jan, 2026

Executive summary

  • Q2 FY25 was challenging due to seasonal weakness in India and a steep increase in raw material costs, leading to a sequential decline in operating margin to 13.6%.

  • Consolidated revenue for Q2 FY25 reached ₹64,370 million, up 2.5% year-over-year, with EBITDA at ₹8,779 million, down 24.3% year-over-year due to raw material inflation.

  • India operations saw single-digit YoY growth in replacement volumes and double-digit growth in exports, but OEM segment remained soft.

  • Europe operations achieved 0.8% YoY revenue growth and improved EBITDA margin by 74 bps, with a strong UHP mix at 46%.

  • Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024, and authorized raising up to ₹10,000 million via NCDs, subject to shareholder approval.

Financial highlights

  • Consolidated revenue for Q2 FY25 was INR 64.4 billion, up 3% year-over-year; H1 FY25 revenue was ₹127,719 million, up from ₹125,241 million YoY.

  • Consolidated EBITDA stood at INR 8.8 billion, with a margin of 13.6%, down from 14.4% in the previous quarter and 18.5% YoY.

  • Consolidated net profit for Q2 FY25 was ₹2,974.55 million, compared to ₹4,742.51 million in Q2 FY24; H1 FY25 net profit was ₹5,994.57 million, down from ₹8,711.59 million YoY.

  • Standalone Q2 FY25 revenue was ₹44,617.40 million, with net profit at ₹1,647.77 million; EBITDA margin fell to 12.1% from 19.1% YoY.

  • European operations revenue was €171 million, up slightly YoY and 17% sequentially; EBITDA margin improved to 14.8%.

Outlook and guidance

  • RM costs are expected to rise slightly in Q3 and decline from Q4 onwards.

  • Replacement demand in India is expected to improve in H2, while OEM demand remains muted.

  • Double-digit growth anticipated in TBR and PCR replacement segments for the full year.

  • European market recovery is expected to continue, with further margin improvement targeted.

  • Board approved fund-raising via NCDs up to ₹10,000 million to support future growth and capital needs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more